SkyAI (SKYA) Aegis Capital Financial Conference summary

Strategic agreements and market opportunities

• Secured a $50 million sales agreement with a major U.S. filler for 10 mL syringes, utilizing most of the current European facility's capacity.

• The agreement is expected to generate early revenue in Q2 2024, with first shipments scheduled imminently.

• Potential expansion could add another 250 million units to the facility, supporting further growth.

• The U.S. customer is moving away from Chinese suppliers due to quality and tariff concerns.

• Additional purchase orders from both U.S. and European customers are anticipated as production scales.

Facility expansion and financing

• Raised funds with Aegis to expand equipment and technology, enabling scale-up for large contracts.

• Facility in Hungary is debt-free, scalable, and focused on smart safety syringe technology.

• A portion of the $20 million financing was used to pay off all long-term debt.

• Plans are underway to expand the European facility and potentially acquire or partner for a U.S. manufacturing site.

• The $50 million agreement serves as a foundation for further investment in prefilled syringe capabilities.

Product innovation and market trends

• Focus on lightweight, accurate, and clean syringe technology, with advantages over glass syringes.

• Prefillable copolymer syringes offer superior drug stability, performance, and manufacturing benefits.

• The global syringe market is rapidly growing, with significant investments from major pharmaceutical and packaging companies.

• FDA support for GLP-1 drugs and the shift to prefilled syringes is driving demand.

• Advanced copolymer technology positions the company to meet increasing demand for prefilled syringes.